- Isomorphic Labs, the AI drug-discovery company founded by former Google DeepMind CEO Demis Hassabis, raised a $5 billion Series C round announced November 17, 2026.
- The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued investment from Alphabet.
- The raise comes three and a half months after Hassabis stepped back as CEO of Google DeepMind.
- Isomorphic last raised $2.1 billion in a Series B round in May 2026.
What Happened
Isomorphic Labs, the AI drug-discovery company Demis Hassabis founded alongside his role at Google DeepMind, raised a $5 billion Series C round announced November 17, 2026, CNBC reported. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining as a new investor and Alphabet continuing to invest.
Why It Matters
The raise lands three and a half months after Hassabis stepped back as CEO of Google DeepMind, underscoring that investors are betting on Isomorphic’s AI-drug-design approach independent of his DeepMind role. The company had already moved toward its first human drug trials earlier in 2026, giving the new funding a concrete near-term use.
Technical Details
Isomorphic says the new capital will accelerate its programs toward clinical trials. The company’s disclosed funding has grown quickly: it raised $2.1 billion in a Series B round in May 2026, and the $5 billion Series C more than doubles that figure in a single round six months later.
Who’s Affected
The raise affects Isomorphic’s drug-discovery pipeline partners and the broader AI-for-biotech sector, where large late-stage checks have concentrated in a small number of companies. Alphabet’s continued participation also ties Google’s balance sheet more closely to an AI-drug-design bet that sits outside Google DeepMind itself.
What’s Next
Isomorphic has not disclosed a specific valuation for the Series C or named which drug programs will be prioritized for the accelerated clinical-trial timeline. Its next disclosed milestone will likely be progress updates on the human trials it had already begun moving toward earlier this year.